‘A Huge Shock To The System’: Doctors Warn About Asthma Inhaler Switch Coming In January

Starting January 1, a medication crucial for the respiratory well-being of thousands of patients is set to vanish from pharmacy shelves, causing concern among physicians about potential delays in patients transitioning to alternatives and securing insurance coverage for them, CNN reports.

Pharmaceutical company GSK has declared the discontinuation of the branded asthma inhaler Flovent, introducing an “authorized generic” version, essentially identical but lacking the recognizable branding.

Physicians specializing in asthma treatment acknowledge that the authorized generic is expected to be equally effective as the branded drug. However, there is apprehension regarding its limited coverage by insurers. This could lead patients to navigate new prescriptions and confront coverage challenges during the peak of the respiratory virus season. Dr. Robyn Cohen from Boston Medical Center expressed, “This medication has been the most commonly used inhaled medication for the past 25 or 30 years. It’s the one that, overwhelmingly, pediatricians reach for when they decide that their patient needs a daily preventive medication.”

Amid the rising concerns about the discontinuation of Flovent and the potential insurance issues with its generic replacement, the situation delves into the intricate aspects of American healthcare and drug pricing. Advocacy groups are mobilizing efforts to disseminate information, urging patients to take preemptive action to ensure uninterrupted access to their medication in the upcoming year.

GSK’s spokesperson justified the shift, citing a commitment to patient welfare and emphasizing that authorized generics offer potentially more affordable alternatives. However, industry experts speculate that the timing of this change aligns with alterations in Medicaid rebates, which might expose GSK to substantial penalties due to past price increases on Flovent.

The legal shift, effective January 1, removes the cap on Medicaid rebates, potentially resulting in pharmaceutical companies having to sell certain drugs to Medicaid at a loss. GSK’s adoption of the authorized generic strategy is seen as a means to maintain profitability while avoiding the impact of the rebate changes. This strategy allows the company to continue reaping some economic benefits without the historical baggage of significant price increases.

Notably, the price of branded Flovent has surged by approximately 47% since 2014, prompting GSK to price the authorized generic lower than the branded version. However, major pharmacy benefit manager CVS Caremark has opted for another branded inhaler, Pulmicort, over the authorized generic versions of Flovent due to cost considerations and favorable insurance coverage.

The lack of broad insurance coverage for the authorized generic of Flovent poses a significant challenge for patients, particularly during the winter respiratory virus season. Patients are advised to proactively seek alternatives and address insurance coverage concerns. Concerns are particularly heightened for patient groups with limited alternatives, such as those with eosinophilic esophagitis, for whom Flovent is a commonly prescribed topical steroid.

{Matzav.com}